TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27889710

Group type: EXPERIMENTAL
Intervention: IV maintenance therapy with phenobarbitone
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups (phenobarbitone and placebo)
Number of subjects: 152
Study: 24848391

Group type: EXPERIMENTAL
Intervention: Subtenon anesthesia
Number of subjects: 304

Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 304
Study: 23796152

Group type: EXPERIMENTAL
Intervention: HeartWare Ventricular Assist System
Number of subjects: 332
Study: 19482306

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted placement
Number of subjects: 77

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 77
Study: 18794651

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specifics not provided)
Number of subjects: 1627
Study: 16177618

Group type: EXPERIMENTAL
Intervention: 4 KKW (4 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 8 KKW (8 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 12 KKW (12 kcal(‐1).kg(‐1).wk(‐1))
Number of subjects: 111
Study: 12732934

Group type: EXPERIMENTAL
Intervention: Endoluminal stenting after tracheal lumen re-establishment
Number of subjects: 16
Study: 11789204

Group type: EXPERIMENTAL
Intervention: Stereotaxic drainage and orally taken Zhuyu Xiaozhong mixture (ZYXZM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Stereotaxic drainage alone
Number of subjects: 61
Study: 8651549

Group type: EXPERIMENTAL
Intervention: 5‐FU plus levamisole (SWOG 8591)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐FU, whole‐abdominal radiation, and tumor boost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5‐FU plus levamisole
Number of subjects: 0
Study: 1531464

Group type: EXPERIMENTAL
Intervention: Intranasal nafarelin 200 micrograms two times a day
Number of subjects: 307

Group type: COMPARATOR
Intervention: Oral danazol 200 mg three times a day
Number of subjects: 307
Study: 6514178

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31829252

Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of a blended training program, local interdisciplinary meetings, and interdisciplinary case conferences.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Interdisciplinary approach of the intervention.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Factors associated with implementation and perceived impact.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall implementation and satisfaction rates.
Number of subjects: 24
Study: 29369090

Group type: EXPERIMENTAL
Intervention: 14-item self-report instrument for physical activity
Number of subjects: 537
Study: 26800903

Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention (algorithm‐based, real‐time tailored feedback and recommendations for behavior change)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care (standard counseling by syringe exchange staff)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Hep‐Net intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 235
Study: 24915052

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg plus Valsartan 80 mg (N30+V80)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg (N60)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Valsartan 160 mg (V160)
Number of subjects: 391
Study: 22168345

Group type: EXPERIMENTAL
Intervention: 1 g of alcohol per kilogram of body mass
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-alcoholic control beverage
Number of subjects: 10
Study: 20224514

Group type: EXPERIMENTAL
Intervention: Concentration-controlled mycophenolate mofetil (MMF) dosing based on mycophenolic acid (MPA) exposure
Number of subjects: 130

Group type: COMPARATOR
Intervention: Fixed-dose mycophenolate mofetil (MMF)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Concentration-controlled mycophenolate mofetil (MMF) dosing
Number of subjects: 130

Group type: COMPARATOR
Intervention: Both groups (Concentration-controlled and Fixed-dose)
Number of subjects: 130
Study: 17428615

Group type: EXPERIMENTAL
Intervention: Smoking Consequences Questionnaire‐Adult (SCQ‐A) Weight Control scores
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: SCQ‐A Weight Control scores
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Reported weight gain at previous attempts
Number of subjects: 385
Study: 16146495

Group type: EXPERIMENTAL
Intervention: Movement Energy Index (MEI) for patients with cervical dystonia
Number of subjects: 6

Group type: COMPARATOR
Intervention: Movement Energy Index (MEI) for controls
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Movement Energy Index (MEI) for patients
Number of subjects: 6
Study: 12442631

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10193967

Group type: EXPERIMENTAL
Intervention: Frequency‐doubled Q‐switched Nd:YAG laser (532 nm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 35% TCA
Number of subjects: 20
Study: 8547373

Group type: EXPERIMENTAL
Intervention: Combined Barthel and Mini-mental State Examination scores
Number of subjects: 0
Study: 1433451

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine alone (3 doses at 0, 1, 2 months)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine + HBIG (3 doses at 0, 1, 2 months)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine alone
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine + HBIG
Number of subjects: 109
Study: 2998663

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30067456

Group type: EXPERIMENTAL
Intervention: 12-week teacher-led intervention to improve actual motor competence (MC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 12-week teacher-led intervention
Number of subjects: 171
Study: 28370973

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment according to bacteriogram sensitivity
Number of subjects: 27

Group type: COMPARATOR
Intervention: Observational group (no treatment)
Number of subjects: 27
Study: 27185197

Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg on days 1 and 8 of the first cycle and day 1 of the second and third cycles (O-ESHAP)
Number of subjects: 62
Study: 24645632

Group type: EXPERIMENTAL
Intervention: CMM (invasive cutaneous malignant melanoma)
Number of subjects: 52869

Group type: EXPERIMENTAL
Intervention: SCC (squamous cell carcinoma)
Number of subjects: 52869

Group type: EXPERIMENTAL
Intervention: Subsequent skin cancers
Number of subjects: 52869

Group type: EXPERIMENTAL
Intervention: Non-skin cancers (oral, lung, colon, breast, prostate, thyroid, leukemia, lymphoma, central nervous system)
Number of subjects: 52869

Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 52869

Group type: EXPERIMENTAL
Intervention: Parental cancer
Number of subjects: 52869
Study: 22620487

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20976845

Group type: EXPERIMENTAL
Intervention: Partially covered sphincterotome
Number of subjects: 387

Group type: COMPARATOR
Intervention: Uncovered sphincterotome
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 387
Study: 18599956

Group type: COMPARATOR
Intervention: Placebo group (N=733)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo group (N=106)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 733
Study: 16162716

Group type: EXPERIMENTAL
Intervention: PiKo‐1 device
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Spirotel device
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mini‐Wright Peak‐Flow Meter
Number of subjects: 38
Study: 12474709

Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 0
Study: 9629050

Group type: EXPERIMENTAL
Intervention: Biofix rods and screws
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard A.O. fixation
Number of subjects: 41
Study: 7939146

Group type: EXPERIMENTAL
Intervention: Oxymetazoline spray
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oxymetazoline solution
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 5
Study: 3219315

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Added sodium chloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very-low-protein meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meals containing 220 g protein/kg dry weight
Number of subjects: 0
Study: 29673108

Group type: EXPERIMENTAL
Intervention: Lenalidomide (25 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lenalidomide plus Dexamethasone (25 mg/day and 40 mg/week)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Patients who achieved ≥PR but did not proceed into the phase 2 trial
Number of subjects: 133
Study: 26667928

Group type: EXPERIMENTAL
Intervention: Low-load Slow Movement Squat Training (LST) - 50% one-repetition maximum (1-RM) load, 3 seconds for lowering/lifting without pause
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-load Normal Speed (LN) - 50% 1-RM load, 1 second for lowering/lifting with 1-second pause
Number of subjects: 16
Study: 24749983

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 803

Group type: COMPARATOR
Intervention: Text intervention
Number of subjects: 803

Group type: COMPARATOR
Intervention: Combination intervention
Number of subjects: 803
Study: 23552127

Group type: EXPERIMENTAL
Intervention: Zofenopril 60 mg and ASA 100 mg
Number of subjects: 682

Group type: COMPARATOR
Intervention: Ramipril 10 mg and ASA
Number of subjects: 682
Study: 20663302

Group type: EXPERIMENTAL
Intervention: Pressure support level of 5 cm H2O
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pressure support level of 15 cm H2O
Number of subjects: 15
Study: 18402900

Group type: EXPERIMENTAL
Intervention: 3-V (1 RV and 2 LV leads)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2-V (1 RV and 1 LV lead)
Number of subjects: 40
Study: 16450089

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1,200 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12834797

Group type: EXPERIMENTAL
Intervention: Sweetened chewing gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsweetened chewing gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sweet taste without chewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sweet taste with chewing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no gum)
Number of subjects: 0
Study: 11029335

Group type: EXPERIMENTAL
Intervention: Exercise-induced bronchoconstriction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methacholine challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Allergen inhalation
Number of subjects: 10
Study: 8930154

Group type: EXPERIMENTAL
Intervention: Naltrexone (3.125, 12.5, 50 and 200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of cocaine and hydromorphone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8403955

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 46
Study: 2868964

Group type: EXPERIMENTAL
Intervention: Azodisal sodium
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 29673132

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20mg/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 101
Study: 27311415

Group type: EXPERIMENTAL
Intervention: 1000 mg calcium supplementation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 2000 mg calcium supplementation
Number of subjects: 65

Group type: COMPARATOR
Intervention: 500 mg calcium supplementation
Number of subjects: 65
Study: 24972105

Group type: EXPERIMENTAL
Intervention: VIPP-TM (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 22855866

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg twice daily for 3 weeks, then 200 mg twice daily for 3 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20727160

Group type: EXPERIMENTAL
Intervention: Wood smoke exposure (PM2.5 concentration of 224 ± 22 μg/m3)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 19
Study: 18666493

Group type: EXPERIMENTAL
Intervention: iBond applied to lesions with sclerosis scale 1 and 2 (n=28)
Number of subjects: 105

Group type: COMPARATOR
Intervention: SB applied to lesions with sclerosis scale 1 and 2 (n=26)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: iBond applied to lesions with sclerosis scale 3 and 4 (n=25)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: iBond applied with prior acid-etching to lesions with sclerosis scale 3 and 4 (n=26)
Number of subjects: 105
Study: 16448252

Group type: EXPERIMENTAL
Intervention: Indirect bonding with antimicrobial varnish applied on etched enamel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indirect bonding control group (no varnish)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Direct bonding with antimicrobial varnish mixed with Transbond MIP primer
Number of subjects: 60
Study: 12818631

Group type: EXPERIMENTAL
Intervention: s.c. melagatran (1-3 mg bid) followed by oral ximelagatran (8-24 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: s.c. melagatran (3 mg bid) followed by oral ximelagatran (24 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: s.c. dalteparin (5000 IU od)
Number of subjects: 0

Group type: COMPARATOR
Intervention: s.c. enoxaparin (40 mg od)
Number of subjects: 0
Study: 10353130

Group type: EXPERIMENTAL
Intervention: Biatrial synchronous pacing (BSP) via epicardial electrodes, initiated in AAI-Mode at a rate of 10 beats/min above the underlying rhythm (maximum 110 beats/min) for 3 days.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional therapy (control group with 9 patients).
Number of subjects: 21
Study: 7546525

Group type: EXPERIMENTAL
Intervention: Low-biocompatible membrane (cuprophane)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-biocompatible membrane (polyacrylonitrile)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isolated hemodialysis (without ultrafiltration)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ultrafiltration (with ultrafiltration)
Number of subjects: 8
Study: 1773905

Group type: EXPERIMENTAL
Intervention: Oral administration of bacterial extracts over 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular benzanthine penicillin
Number of subjects: 0
Study: 6258375

Group type: EXPERIMENTAL
Intervention: pancuronium 0.01 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: pancuronium 0.015 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: gallamine 0.3 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: gallamine 0.4 mg/kg
Number of subjects: 40
Study: 29947813

Group type: EXPERIMENTAL
Intervention: Susceptibility Vessel Sign (SVS+)
Number of subjects: 287
Study: 29047376

Group type: EXPERIMENTAL
Intervention: Women's education (primary education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's education (secondary education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher women's education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher mother's education (primary)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher mother's education (secondary)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher men's education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher education of any household member
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Households where mother's education was better than the best-educated man
Number of subjects: 0
Study: 25856682

Group type: EXPERIMENTAL
Intervention: 1600 μg of salbutamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23954900

Group type: EXPERIMENTAL
Intervention: Assay-sensitive regimen
Number of subjects: 262

Group type: COMPARATOR
Intervention: Assay-intermediate and resistant groups (I+R)
Number of subjects: 262
Study: 21046356

Group type: EXPERIMENTAL
Intervention: Rapamycin monotherapy (0.1 mg/kg; target trough levels 8-10 ng/ml; 26-314 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rapamycin monotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (14 patients waiting for islet transplant without rapamycin pre-conditioning)
Number of subjects: 22
Study: 18506181

Group type: EXPERIMENTAL
Intervention: Erlotinib at 50 mg (cohort 1), 100 mg (cohort 2a), or 75 mg (cohort 2b) day(‐1) for up to six cycles with docetaxel (75 mg m(‐2)) and carboplatin (AUC 5) on day 1 of a 3-week cycle.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single-agent maintenance erlotinib at 100-150 mg day(‐1) after initial treatment.
Number of subjects: 45
Study: 16395617

Group type: EXPERIMENTAL
Intervention: Anterior hemivertebrectomy followed by posterior excision, posterior instrumentation, and fusion.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Posterior excision followed by anterior hemivertebra body excision, anterior instrumentation, and fusion.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both groups (anterior and posterior techniques)
Number of subjects: 26
Study: 14604045

Group type: EXPERIMENTAL
Intervention: Randomized and stratified investigation by telephone interview
Number of subjects: 502
Study: 10928428

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg progesterone vaginal gel) twice daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg progesterone vaginal gel) once daily
Number of subjects: 345

Group type: COMPARATOR
Intervention: i.m. progesterone (100 mg)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: All treatment groups (Crinone and i.m. progesterone)
Number of subjects: 345
Study: 8793333

Group type: EXPERIMENTAL
Intervention: 0.124 IU/kgBW/week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.250 IU/kgBW/week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.375 IU/kgBW/week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1345029

Group type: EXPERIMENTAL
Intervention: Infusion of ioxaglate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infusion of iopamidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control measures (blood pressure, heart rate, circulating granulocytes)
Number of subjects: 20
Study: 6205060

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g
Number of subjects: 78

Group type: COMPARATOR
Intervention: Mezlocillin 2 g
Number of subjects: 78
Study: 29712745

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment
Number of subjects: 0
Study: 28258928

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol 400mg every 12h for 8 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 26237001

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% 10 mL
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ropivacaine 0.1% 30 mL
Number of subjects: 26
Study: 24144761

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 60
Study: 21943294

Group type: EXPERIMENTAL
Intervention: Web-based self-help therapy (6-week duration, based on Cognitive Behavioural Therapy, Motivational Interviewing, and self-control practices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based self-help therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly psycho-educative information with a quiz (control group)
Number of subjects: 0
Study: 17522607

Group type: EXPERIMENTAL
Intervention: Phoscalim
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycollagene
Number of subjects: 20

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 20
Study: 16582527

Group type: EXPERIMENTAL
Intervention: Phase I periodontal treatment including scaling, root planning, and 0.2% chlorhexidine mouth rinse for one week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phase I periodontal treatment
Number of subjects: 30
Study: 14513774

Group type: EXPERIMENTAL
Intervention: Toki‐shakuyaku‐san
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oral iron preparation
Number of subjects: 25
Study: 10725488

Group type: EXPERIMENTAL
Intervention: Intraoperative lymph node palpation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 126
Study: 8736653

Group type: EXPERIMENTAL
Intervention: terbutaline Turbuhaler (0.5 mg t.i.d.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: salbutamol Rotahaler (0.4 mg t.i.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: terbutaline Turbuhaler
Number of subjects: 32

Group type: COMPARATOR
Intervention: salbutamol Rotahaler
Number of subjects: 32
Study: 1434838

Group type: EXPERIMENTAL
Intervention: TAD (for induction and consolidation) followed by monthly myelosuppressive maintenance for 3 years; second induction course either TAD or HAM for patients less than 60 years.
Number of subjects: 900

Group type: COMPARATOR
Intervention: Allogeneic BMT in first CR
Number of subjects: 900

Group type: COMPARATOR
Intervention: Autologous BMT in first CR
Number of subjects: 900